Oxaliplatin

被引:217
作者
Graham, J [1 ]
Muhsin, M [1 ]
Kirkpatrick, P [1 ]
机构
[1] Decis Resources Int, London WC1B 4HQ, England
关键词
D O I
10.1038/nrd1287
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Oxaliplatin (Eloxatin; Sanofi-Synthelabo) is the first platinum-based anticancer drug to be approved for the treatment of colorectal cancer, a major cause of cancer deaths worldwide. Following European approval in 1999, has approval of oxaliplatin by the US FDA in August 2002 set it on the road to becoming a blockbuster?
引用
收藏
页码:11 / 12
页数:2
相关论文
共 8 条
[1]  
DEGRAMONT A, 2003, P AN M AM SOC CLIN, V22, P253
[2]   Cellular and molecular aspects of drugs of the future: oxaliplatin [J].
Di Francesco, AM ;
Ruggiero, A ;
Riccardi, R .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (11) :1914-1927
[3]   A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].
Goldberg, RM ;
Sargent, DJ ;
Morton, RF ;
Fuchs, CS ;
Ramanathan, RK ;
Williamson, SK ;
Findlay, BP ;
Pitot, HC ;
Alberts, SR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30
[4]   Structure, recognition, and processing of cisplatin-DNA adducts [J].
Jamieson, ER ;
Lippard, SJ .
CHEMICAL REVIEWS, 1999, 99 (09) :2467-2498
[5]   5-Fluorouracil: Mechanisms of action and clinical strategies [J].
Longley, DB ;
Harkin, DP ;
Johnston, PG .
NATURE REVIEWS CANCER, 2003, 3 (05) :330-338
[6]  
Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2
[7]  
Raymond E, 1998, SEMIN ONCOL, V25, P4
[8]   Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel [J].
Rixe, O ;
Ortuzar, W ;
Alvarez, M ;
Parker, R ;
Reed, E ;
Paull, K ;
Fojo, T .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (12) :1855-1865